U.S. Nuclear Medicine Market Size & Outlook, 2023-2030
U.S. nuclear medicine market, 2018-2030 (US$M)
Related Markets
U.S. nuclear medicine market highlights
- The U.S. nuclear medicine market generated a revenue of USD 4,339.7 million in 2023 and is expected to reach USD 10,433.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 13.4% from 2024 to 2030.
- In terms of segment, diagnostics was the largest revenue generating product in 2023.
- Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
Nuclear medicine market data book summary
| Market revenue in 2023 | USD 4,339.7 million |
| Market revenue in 2030 | USD 10,433.2 million |
| Growth rate | 13.4% (CAGR from 2023 to 2030) |
| Largest segment | Diagnostics |
| Fastest growing segment | Therapeutics |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 42.3% of the global nuclear medicine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. nuclear medicine market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,133.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nuclear Medicine Market Scope
Nuclear Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. nuclear medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 67.94% in 2023. Horizon Databook has segmented the U.S. nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. has two major generator manufacturers: Nordion and Lantheus Medical Imaging, Inc. However, supply of Tc-99 from these companies is at stake, as the NRU has stopped the production of Mo-99. To mitigate this shortage, new avenues in radioisotopes are being explored to find new processes for production or replacement of Tc-99.
Furthermore, presence of major players in the country, such as Lantheus and GE Healthcare, is expected to support its major market share. Moreover, new market entrants, such as Positron Corporation, are currently developing Sr-82/Rb-82 generators, with potential access to third-party generators in the future, to overcome the scarcity of Tc-99 generators.
In addition, presence of favorable reimbursement scenario for radiopharmaceuticals in the country is anticipated to boost market growth. For instance, in July 2019, H.R. 3772 (The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019) was introduced to improve Medicare payments for imaging purposes.
Reasons to subscribe to U.S. nuclear medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. nuclear medicine market databook
-
Our clientele includes a mix of nuclear medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into U.S. nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. nuclear medicine market size, by product, 2018-2030 (US$M)
U.S. Nuclear Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
